T1	Participants 600 721	multinational double-blind trial in postmenopausal women with HR+ breast cancer ineligible for breast-conserving surgery.
T2	Participants 1007 1065	human epidermal growth factor receptor HER1/HER2+ subgroup
T3	Participants 1536 1546	ER+ tumors
T4	Participants 1923 1984	postmenopausal women with HR+ locally advanced breast cancer.
